What is the appropriate management of a patient with Mycoplasma pneumoniae infection presenting with Fuchs syndrome (mucosal‑only Stevens–Johnson syndrome) affecting the respiratory system?

Management of Fuchs Syndrome (Mycoplasma pneumoniae-Associated Mucositis)

Fuchs syndrome, also termed Mycoplasma pneumoniae-associated mucositis (MPAM), should be managed primarily with supportive care focused on aggressive mucosal protection, appropriate antimicrobial therapy with macrolides or fluoroquinolones, and consideration of systemic corticosteroids or IVIG for severe cases, though evidence for immunomodulatory therapy remains limited. 1, 2

Recognition and Diagnosis

This condition represents a distinct phenotype within the Stevens-Johnson syndrome spectrum characterized by:

• Predominantly mucous membrane involvement with minimal or absent cutaneous lesions 1
• Oral lesions present in 100% of cases, followed by ocular involvement (97%) and urogenital lesions (78%) 3
• Associated respiratory symptoms with fever and confirmed M. pneumoniae infection (typically by serology IgM or PCR) 3, 4
• Primarily affects children and young adults (median age 13.5 years), with male predominance 5, 3

Critical pitfall: Despite minimal skin involvement occurring in up to 31% of MPAM cases, the absence of extensive cutaneous lesions distinguishes this from classic SJS/TEN 3

Immediate Management Protocol

Discontinue Potential Triggers

• Immediately stop any suspected culprit medications, though M. pneumoniae is the infectious trigger rather than drugs in this entity 1

Antimicrobial Therapy

Macrolides remain first-line despite variable response:

• Macrolides were administered in 81% of reported cases, though failure, relapse, or worsening occurred in one-third of patients 3
• Alternative: Fluoroquinolones (levofloxacin) have demonstrated effectiveness in adult cases when combined with corticosteroids 6

Key consideration: The inflammatory mechanism may be more important than the antimicrobial effect, explaining variable antibiotic responses 3

Mucosal Care - Oral Cavity

Implement aggressive oral hygiene and pain control:

• Clean mouth daily with warm saline mouthwashes or oral sponge, sweeping gently in labial and buccal sulci to prevent fibrotic scarring 1
• Apply benzydamine hydrochloride spray every 3 hours, particularly before eating 1
• For inadequate pain control: viscous lidocaine 2% (15 mL per application) or cocaine mouthwashes 2-5% three times daily for severe discomfort 1
• Antiseptic oral rinse twice daily (1.5% hydrogen peroxide or 0.2% chlorhexidine digluconate, diluted up to 50% to reduce soreness) 1
• Topical corticosteroid: betamethasone sodium phosphate 0.5 mg in 10 mL water as 3-minute rinse-and-spit four times daily, or clobetasol propionate 0.05% mixed with Orabase applied directly to affected mucosae 1

Mucosal Care - Ocular

Early ophthalmology consultation is mandatory:

• Regular examination for purulent keratoconjunctivitis and eyelid involvement 1
• Aggressive topical therapy to prevent long-term sequelae including potential bronchiolitis obliterans 7

Mucosal Care - Urogenital

Prevent adhesions and strictures:

• Apply white soft paraffin ointment every 4 hours to urogenital skin and mucosae 1
• Use Mepitel dressings to eroded areas in vulva and vagina to reduce pain and prevent adhesions 1
• Insert dilator or tampon wrapped in Mepitel into vagina to prevent synechiae formation 1
• Consider potent topical corticosteroid ointment once daily to involved, non-eroded surfaces 1
• Catheterize all patients to prevent urethral strictures 1

Immunomodulatory Therapy

The evidence for systemic immunomodulation remains equivocal:

• No reliable evidence exists for benefits of prednisolone, IVIG, anti-TNF biologics, or ciclosporin in SJS/TEN spectrum 7
• However, case reports suggest potential benefit: One adult case responded to levofloxacin plus prednisolone 6, and systemic corticosteroids were used in 31% of MPAM cases with IVIG in 9% 3
• If instituted, administer under specialist supervision in context of clinical research or case registry 7

Clinical judgment: Given the inflammatory pathogenesis suggested by the literature, systemic anti-inflammatory treatment may be more important than antimicrobials alone, particularly in severe cases 3

Supportive Care

• Fluids and nutritional support (nasogastric feeding may be required for severe oral involvement) 2
• Aggressive pain control 2
• Monitor for secondary bacterial or candidal infections: treat with nystatin oral suspension 100,000 units four times daily or miconazole oral gel 5-10 mL four times daily 1
• Consider HSV reactivation if oral mucosa healing is slow 1

Prognosis and Follow-up

The prognosis is uniformly excellent:

• Complete recovery occurs in nearly all patients with no long-term sequelae reported in MPAM cases 5, 3
• Treatment appears to have little effect on overall course, which is typically self-limited 5

Counsel patients regarding:

• Potential long-term problems including respiratory complications (particularly bronchiolitis obliterans), though rare in MPAM 7
• Risk of recurrence with future M. pneumoniae infections 7
• The infectious rather than drug-related etiology, avoiding unnecessary medication avoidance 7